department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Eyebiotech Ltd · pharmadog

PUBLIC COMPANY

Eyebiotech Ltd

updated 1mo ago

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

1

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Unknown

Upcoming

no upcoming catalysts on record

Recent(90d)

phase 1 2 completion (1)

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Eyebiotech Ltd jobs →

News

no news has mentioned this company yet

identifiers

source

globaldata

mentioned in

0news items

entity-linker matched

phase 1 2 completion

Eyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)

Active trials

phase3A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)recruitingn=960
phase3A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)recruitingn=960
phase2A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degenerationactive not recruitingn=38
phase3A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMEactive not recruitingn=1,054
phase2A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)completedn=33
phase2A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVOrecruitingn=160
phase3A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMEactive not recruitingn=984

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagOphthalmology1 co-mentions · 1 sources
tagDiabetic Macular Edema1 co-mentions · 1 sources
drugMK-87481 co-mentions · 1 sources